Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
NEW YORK, Nov. 30, 2015 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Nevada on behalf of investors who purchased Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) securities between May 7, 2015 and October 23, 2015.
Click here to learn about the case: http://docs.wongesq.com/SPPI-Info-Request-Form-1012. There is no cost or obligation to you.
The complaint alleges that Spectrum Pharmaceuticals violated federal securities laws by disseminating materially false and misleading information and failing to disclose material facts, causing the stock to trade at artificially inflated prices.
On October 23, 2015, Spectrum announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) in response to its New Drug Application seeking clearance for Evomela, indicating that the FDA cannot approve the application in its present form. Upon this news, shares of Spectrum Pharmaceuticals fell more than 20% on intraday trading.
If you suffered a loss in Spectrum Pharmaceuticals you have until January 4, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://docs.wongesq.com/SPPI-Info-Request-Form-1012.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
